“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Context Therapeutics
Context Therapeutics is a clinical-stage biopharma company developing therapeutics for solid tumors. The core pipeline focus is now on CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, which is in preclinical development with plans for an IND application filing in Q124.
Context Therapeutics — 4 videos in collection
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with hormone-dependent cancer.
• Tell us about the types of cancer that affect predominantly women and Context Therapeutics’ distinctive approach in this area?
• Is it correct that you are currently unique in this large market?
• How did you identify this opportunity?
• Tell us about your development pipeline, including your lead asset ONA-XR?
• Please explain the term ‘bispecific monoclonal antibody’ and why is it relevant in this context?
• How does the recent acquisition fit in with your future plans and does it indicate other in-licensing opportunities in the near or medium term?
• What can you tell us about the plan to commercialise your asset pipeline?
• Which options are you considering for further fund-raising?
• Which milestones should investors focus on in the coming year?
Get access to the very latest content matched to your personal investment style.
